Notably, PD-1 blockade further augmented the infiltration of CD8+ T cells and CD11c+ DCs, suggesting that anti-PD-1 treatment and ANXA1 knockdown synergistically promote the anti-tumor immune response. Here, PDCD1 is linked to neoplasm.